The proceeds will be used to accelerate the PREEMPT CRC� clinical trial for Freenome's blood test for colorectal cancer screening and precancerous lesion detection, advance a pipeline of blood tests for both the early detection and early intervention of additional cancers, and continue building the company's proprietary multiomics platform.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

279 East Grand Ave. 5th Floor
San Francisco, CA 94080
USA

Phone

Undisclosed

Website

www.freenome.com

Email Address

[email protected]

Overview

Freenome is the dynamic collection of genetic material floating in your blood (cell-free) derived from the trillions of cells in your body. It is your living cell-free genome changing over time and space.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Gabriel Otte

Chief Financial Officer

William Quirk

Chief Medical Officer

Girish Putcha

Chief Operating Officer

Riley Ennis

Chief Scientific Officer

Jimmy Lin

VP - Bus. Development

Michael Nolan

VP - Client Services

Charles Roberts

Browse more venture capital transactions:

Prev: 8/31/2020: ChartHop venture capital transaction
Next: 8/31/2020: Verto Health venture capital transaction

Share this article

News on VC Transactions

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary